CHMP found that Pfizer’s Herceptin biosimilar was similar to EU-licensed trastuzumab in terms of efficacy, safety, immunogenicity, and pharmacokinetics when used as first-line treatment.

Its Rituxan (rituximab) biosimilar, launched this week and branded as Ruxience, will be marketed at $71.68 per 10mg, a 24% discount compared with the original. Pfizer's Herceptin (trastuzumab ...

Belgian anti-trust regulators are probing Roche over concerns that the drug company took steps to delay the entry of biosimilar versions ... Rituximab and Trastuzumab – and that its tactics ...

To date, the company's launched products include HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name: HERCESSI in the U.S., Zercepac in Europe), a China ...

Introduction Biosimilar monoclonal antibodies (mAbs) are biologic drugs designed to be highly similar to already approved reference monoclonal ...

The global adalimumab, infliximab, etanercept and trastuzumab biosimilars market reached ... Fresenius SE & Co. KGaA with 5.5%, Pfizer Inc. with 5.4%, Teva Pharmaceutical Industries Ltd. with ...